Andrew Xian Chen
Fondateur chez Cali Biosciences Co. Ltd.
Profil
Andrew Xian Chen is the founder of SD Pharmaceuticals, Inc. (founded in 2004), Encore Therapeutics, Inc. (founded in 2006), LATITUDE Pharmaceuticals, Inc. (founded in 2003), and Cali Biosciences Co. Ltd.
(founded in 2021), where he holds the title of Executive Director & Chief Scientific Officer.
He is currently the Chief Executive Officer & Director at Cali Biosciences Us LLC and a Director at Cali Shenzhen Biosciences Co. Ltd.
Dr. Chen received a doctorate degree from the College of Pharmacy & Health Sciences in 1992, a graduate degree from the same institution in 1988, and an undergraduate degree from Zhejiang University School of Medicine in 1983.
Postes actifs de Andrew Xian Chen
| Sociétés | Poste | Début |
|---|---|---|
Cali Biosciences Co. Ltd.
 Cali Biosciences Co. Ltd. BiotechnologyHealth Technology Cali Biosciences Co. Ltd. operates as a biotechnology company dedicated to the research and development of new drugs for the perioperative space based on drug delivery platforms and other patented technologies. Its product focuses on non-opioid post-operative pain management, anti-inflammatory pain control, anesthesia, and sedation. The company was founded by Dibang Lin and Andrew Xian Chen on March 17, 2021 and is headquartered in Shenzhen, China. | Fondateur | 17/03/2021 |
| Cali Biosciences Us LLC | Directeur Général | - |
| Cali Shenzhen Biosciences Co. Ltd. | Directeur/Membre du Conseil | - |
Anciens postes connus de Andrew Xian Chen
| Sociétés | Poste | Fin |
|---|---|---|
SD Pharmaceuticals, Inc.
 SD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Savara, Inc., SD Pharmaceuticals, Inc. is a company that researches and develops reformulated treatment products for cancer and other infectious diseases. The company is based in Carlsbad, CA. The company was founded by Andrew Xian Chen. SD Pharmaceuticals was acquired by Mast Therapeutics, Inc. on April 28, 2006 for $9.89 million. | Fondateur | - |
| Encore Therapeutics, Inc. | Fondateur | - |
LATITUDE Pharmaceuticals, Inc.
 LATITUDE Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services LATITUDE Pharmaceuticals, Inc. provides generic drug formulation services. The private company is based in San Diego, CA. The company was founded by Andrew Xian Chen. | Fondateur | - |
Formation de Andrew Xian Chen
| College of Pharmacy & Health Sciences | Doctorate Degree |
| Zhejiang University School of Medicine | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Cali Biosciences Co. Ltd.
Cali Biosciences Co. Ltd. BiotechnologyHealth Technology Cali Biosciences Co. Ltd. operates as a biotechnology company dedicated to the research and development of new drugs for the perioperative space based on drug delivery platforms and other patented technologies. Its product focuses on non-opioid post-operative pain management, anti-inflammatory pain control, anesthesia, and sedation. The company was founded by Dibang Lin and Andrew Xian Chen on March 17, 2021 and is headquartered in Shenzhen, China. | Health Technology |
| Cali Biosciences Us LLC | |
| Cali Shenzhen Biosciences Co. Ltd. | |
LATITUDE Pharmaceuticals, Inc.
LATITUDE Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services LATITUDE Pharmaceuticals, Inc. provides generic drug formulation services. The private company is based in San Diego, CA. The company was founded by Andrew Xian Chen. | Commercial Services |
SD Pharmaceuticals, Inc.
SD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Savara, Inc., SD Pharmaceuticals, Inc. is a company that researches and develops reformulated treatment products for cancer and other infectious diseases. The company is based in Carlsbad, CA. The company was founded by Andrew Xian Chen. SD Pharmaceuticals was acquired by Mast Therapeutics, Inc. on April 28, 2006 for $9.89 million. | Health Technology |
| Encore Therapeutics, Inc. |